Adrenomedullin: A vasoactive agent for sporadic and hereditary vascular cognitive impairment.
Adrenomedullin
Angiogenesis
Anti-inflammation
Clinical trial
Vascular cognitive impairment
Journal
Cerebral circulation - cognition and behavior
ISSN: 2666-2450
Titre abrégé: Cereb Circ Cogn Behav
Pays: Netherlands
ID NLM: 101774849
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
12
2020
revised:
14
02
2021
accepted:
26
02
2021
entrez:
3
11
2022
pubmed:
4
3
2021
medline:
4
3
2021
Statut:
epublish
Résumé
Adrenomedullin (AM) is an endogenous peptide mainly secreted from endothelial cells, which has multiple physiological actions such as anti-inflammation, vasodilation, vascular permeability regulation and angiogenesis. Blood AM levels are upregulated in a variety of pathological states including sepsis, severe COVID-19, acute ischemic stroke and vascular cognitive impairment with white matter changes, likely serving as a compensatory biological defense response against infection and ischemia. AM is currently being tested in clinical trials for ulcerative colitis, Crohn's disease, severe COVID-19 for its anti-inflammatory properties and in ischemic stroke for its additional angiogenic action. AM has been proposed as a therapeutic option for vascular cognitive impairment as its arteriogenic and angiogenic properties are thought to contribute to a slowing of cognitive decline in mice after chronic cerebral hypoperfusion. As AM promotes differentiation of oligodendrocyte precursor cells into mature oligodendrocytes under hypoxic conditions, AM could also be used in the treatment of CADASIL, where reduced oxygen delivery is thought to lead to the death of hypoxia-prone oligodendrocytes. AM therefore holds potential as an innovative therapeutic drug, which may regenerate blood vessels, while controlling inflammation in cerebrovascular diseases.
Identifiants
pubmed: 36324729
doi: 10.1016/j.cccb.2021.100007
pii: S2666-2450(21)00004-0
pmc: PMC9616331
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100007Informations de copyright
© 2021 The Authors. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Dr. Ihara reports personal fees from Daiichi Sankyo, personal fees from Eisai and Bayer, grants from Panasonic, Bristol-Myers Squibb and Otsuka Pharmaceutical, outside the submitted work; Dr. Washida has nothing to disclose; Dr. Yoshimoto reports other from Takeda Pharmaceutical Company Limited, outside the submitted work; Dr. Saito has nothing to disclose.
Références
Clin Sci (Lond). 2017 Sep 28;131(19):2451-2468
pubmed: 28963120
Stroke. 2011 Apr;42(4):1122-8
pubmed: 21393586
Intern Med. 2019 Jun 1;58(11):1573-1576
pubmed: 30713309
Front Aging Neurosci. 2020 May 14;12:130
pubmed: 32477100
J Neuroendocrinol. 2002 Apr;14(4):283-93
pubmed: 11963825
Neuroreport. 2011 Jun 22;22(9):442-7
pubmed: 21558971
Crit Care. 2020 Aug 28;24(1):527
pubmed: 32859259
Front Immunol. 2018 Feb 19;9:292
pubmed: 29520277
J Neurol. 2020 Jul;267(7):2117-2122
pubmed: 32246253
J Cereb Blood Flow Metab. 2009 Nov;29(11):1769-79
pubmed: 19568255
Neurosci Lett. 2015 Jun 15;597:164-9
pubmed: 25936593
Front Neurol. 2019 May 08;10:490
pubmed: 31139139
Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60
pubmed: 8387282
Circulation. 2000 Feb 8;101(5):498-503
pubmed: 10662746
Int J Stroke. 2018 Feb;13(2):207-216
pubmed: 27807280
Drug Des Devel Ther. 2020 Jan 06;14:1-11
pubmed: 32021087
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11480-4
pubmed: 8524787
Drug Discov Today. 2017 Feb;22(2):454-462
pubmed: 27856346
Drug Dev Res. 2017 Jun;78(3-4):129-134
pubmed: 28449192
Biochem Pharmacol. 2003 Dec 1;66(11):2107-15
pubmed: 14609735
J Cardiovasc Pharmacol. 2002 May;39(5):754-60
pubmed: 11973420
Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1432-7
pubmed: 15886352
PLoS One. 2013 Jul 22;8(7):e68768
pubmed: 23894342
J Gastroenterol. 2021 Feb;56(2):147-157
pubmed: 33140199
Peptides. 2014 Jul;57:118-21
pubmed: 24874704
J Atheroscler Thromb. 2017 Dec 1;24(12):1267-1281
pubmed: 28904253
Stem Cell Res. 2015 Jul;15(1):68-74
pubmed: 26002630
Int J Neurosci. 2014 Apr;124(4):271-80
pubmed: 23968191
Clin Neuropharmacol. 2020 Sep/Oct;43(5):146-150
pubmed: 32947425
Braz J Cardiovasc Surg. 2020 Jun 01;35(3):314-322
pubmed: 32549103
Dig Dis Sci. 2016 Mar;61(3):872-80
pubmed: 26470867
Life Sci. 1995;57(8):PL87-90
pubmed: 7637545
N Engl J Med. 2007 Aug 9;357(6):562-71
pubmed: 17687131
Mol Med Rep. 2016 May;13(5):3724-34
pubmed: 27035412
J Alzheimers Dis. 2017;56(4):1253-1262
pubmed: 28234256
Dis Model Mech. 2013 Sep;6(5):1246-59
pubmed: 23720232
Peptides. 2014 Dec;62:21-31
pubmed: 25252154
J Clin Endocrinol Metab. 1997 Jan;82(1):95-100
pubmed: 8989240
Crit Care. 2018 Mar 21;22(1):79
pubmed: 29562917
Acta Neuropathol. 2016 May;131(5):659-85
pubmed: 27062261
Sci Rep. 2016 Sep 19;6:33495
pubmed: 27640364
Mol Cell Neurosci. 2011 Oct;48(2):151-60
pubmed: 21803157
Biochem Biophys Res Commun. 1994 Aug 30;203(1):631-9
pubmed: 8074714
Endocrinology. 2006 Apr;147(4):1642-53
pubmed: 16384868
J Neurochem. 2018 Mar;144(5):617-633
pubmed: 29210074
Hypertension. 2017 Jan;69(1):60-70
pubmed: 27821617
Circ Res. 2005 Sep 16;97(6):512-23
pubmed: 16166562
J Neurosci. 2009 Apr 8;29(14):4351-5
pubmed: 19357263
Stroke Res Treat. 2018 Nov 27;2018:3238165
pubmed: 30598741
Stroke. 2009 Mar;40(3 Suppl):S20-3
pubmed: 19064797
Ann Clin Transl Neurol. 2016 Sep 28;3(11):844-853
pubmed: 27844030
J Biol Chem. 1995 Mar 3;270(9):4412-7
pubmed: 7876206
Acta Neuropathol Commun. 2019 Nov 21;7(1):187
pubmed: 31753008
Stroke. 2016 Feb;47(2):554-60
pubmed: 26742799